Can antiretroviral therapy ever be stopped?

Research output: Contribution to journalArticle

Abstract

A pool of latently infected CD4+ T cells is established within the first few weeks of HIV infection. Because these memory T cells are inactive, the viral DNA integrated into their chromosomes remains invisible to immune surveillance and to antiretrovirals. Research shows that this reservoir of infected memory T cells does not decay in a clinically meaningful time frame - that is, within 60 years - in patients being treated with potent combination antiretrovirals. Even a hypothetical regimen that prevents any new infection of cells would not hasten the decay of this latent reservoir. Treatments that activate this reservoir have been studied in patients with suppressed viremia, but such interventions are highly toxic and have not succeeded so far. Studying rare individuals who manage to control activation of these latent cells may provide important clues to long-term control of HIV infection.

Original languageEnglish (US)
Pages (from-to)224-229
Number of pages6
JournalThe AIDS reader
Volume10
Issue number4
StatePublished - 2000

Fingerprint

T-Lymphocytes
HIV Infections
Poisons
Viremia
Viral DNA
Therapeutics
Chromosomes
Infection
Research

Keywords

  • Decay rates
  • Eradication
  • HIV DNA
  • Interleukin-2
  • Latent infection
  • Memory CD4 T cells

ASJC Scopus subject areas

  • Virology
  • Medicine(all)

Cite this

Can antiretroviral therapy ever be stopped? / Siliciano, Robert F.

In: The AIDS reader, Vol. 10, No. 4, 2000, p. 224-229.

Research output: Contribution to journalArticle

@article{cd85fb370dfa42b0b9d538864c8acc7a,
title = "Can antiretroviral therapy ever be stopped?",
abstract = "A pool of latently infected CD4+ T cells is established within the first few weeks of HIV infection. Because these memory T cells are inactive, the viral DNA integrated into their chromosomes remains invisible to immune surveillance and to antiretrovirals. Research shows that this reservoir of infected memory T cells does not decay in a clinically meaningful time frame - that is, within 60 years - in patients being treated with potent combination antiretrovirals. Even a hypothetical regimen that prevents any new infection of cells would not hasten the decay of this latent reservoir. Treatments that activate this reservoir have been studied in patients with suppressed viremia, but such interventions are highly toxic and have not succeeded so far. Studying rare individuals who manage to control activation of these latent cells may provide important clues to long-term control of HIV infection.",
keywords = "Decay rates, Eradication, HIV DNA, Interleukin-2, Latent infection, Memory CD4 T cells",
author = "Siliciano, {Robert F}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "224--229",
journal = "AIDS Reader",
issn = "1053-0894",
publisher = "CMP Healthcare Media LLC",
number = "4",

}

TY - JOUR

T1 - Can antiretroviral therapy ever be stopped?

AU - Siliciano, Robert F

PY - 2000

Y1 - 2000

N2 - A pool of latently infected CD4+ T cells is established within the first few weeks of HIV infection. Because these memory T cells are inactive, the viral DNA integrated into their chromosomes remains invisible to immune surveillance and to antiretrovirals. Research shows that this reservoir of infected memory T cells does not decay in a clinically meaningful time frame - that is, within 60 years - in patients being treated with potent combination antiretrovirals. Even a hypothetical regimen that prevents any new infection of cells would not hasten the decay of this latent reservoir. Treatments that activate this reservoir have been studied in patients with suppressed viremia, but such interventions are highly toxic and have not succeeded so far. Studying rare individuals who manage to control activation of these latent cells may provide important clues to long-term control of HIV infection.

AB - A pool of latently infected CD4+ T cells is established within the first few weeks of HIV infection. Because these memory T cells are inactive, the viral DNA integrated into their chromosomes remains invisible to immune surveillance and to antiretrovirals. Research shows that this reservoir of infected memory T cells does not decay in a clinically meaningful time frame - that is, within 60 years - in patients being treated with potent combination antiretrovirals. Even a hypothetical regimen that prevents any new infection of cells would not hasten the decay of this latent reservoir. Treatments that activate this reservoir have been studied in patients with suppressed viremia, but such interventions are highly toxic and have not succeeded so far. Studying rare individuals who manage to control activation of these latent cells may provide important clues to long-term control of HIV infection.

KW - Decay rates

KW - Eradication

KW - HIV DNA

KW - Interleukin-2

KW - Latent infection

KW - Memory CD4 T cells

UR - http://www.scopus.com/inward/record.url?scp=0034056278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034056278&partnerID=8YFLogxK

M3 - Article

C2 - 10808605

AN - SCOPUS:0034056278

VL - 10

SP - 224

EP - 229

JO - AIDS Reader

JF - AIDS Reader

SN - 1053-0894

IS - 4

ER -